Lantern Pharma (LTRN) earnings

Lantern Pharma Inc.· Health Care

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Lantern Pharma earnings: last reported Fri, 14 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	Unavailable	—	Quarterly, as filed	Quarter to Jun 2026	Not in the filed figures for the quarter to jun 2026. No older figure is substituted.
Operating margin	Unavailable	—	Operating profit / revenue	Quarter to Jun 2026	Not in the filed figures for the quarter to jun 2026. No older figure is substituted.
Net profit	-7.1 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$0.64 −4.48% · −$0.03

Last close Oct 19, 2026 · US · USD

Performance −83.9% 1Y

1Y: $3.97 on 17 Oct 2025 → $0.64. High $4.17 (30 Jun 2026), low $0.64 (19 Oct 2026).

Previous close: $0.67
52-week range: $0.64 – $4.17
One year: −84.47%

Overview

Symbol: LTRN
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: −63% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Operating profit	-5	-6	-5	-5	-4	-4	-3	-4
Net profit	-5	-6	-5	-4	-4	-4	-3	-7
EPS ($ per share)	-0.42	—	-0.42	-0.40	-0.39	—	-0.30	-0.57

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0
Reserves	-7	-13	-25	-39	-55	-76	-93
Total liabilities	0	1	2	3	3	4	5
Fixed assets	0	0	0	0	0	0	0
Investments	—	—	19	18	19	17	6
Total assets	1	20	74	59	44	26	11

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	-2	-6	-11	-13	-14	-18	-16
Cash from investing	-0	-0	-20	0	-1	3	11
Cash from financing	3	24	63	-2	-0	0	1
Net cash flow	—	—	33	-15	-16	-14	-3
Capital expenditure	—	—	-0	-0	-0	-0	-0
Free cash flow	—	—	-11	-13	-14	-18	-16

Source: Inve data · cash flow · to Dec 2025

Insider filings

2 filings, all on May 12, 2026.

Open market

decisions to buy or sell

Purchases

$200.0K

2 purchases by 2 insiders

Sales

None

No insider sold shares.

Who traded

open market only

Insider	Bought	Sold	Last filing
KEYSER D JEFFREY	$100.0K	—	May 12, 2026
Schalop Lee Troy	$100.0K	—	May 12, 2026

Latest filings (50)

Date	Insider	What	Shares	Value
May 12, 2026	KEYSER D JEFFREY Director	Purchase	48,544	$100.0K
May 12, 2026	Schalop Lee Troy Director	Purchase	48,544	$100.0K
Jun 13, 2025	Kreis Leslie W. 10% owner	Sale	12,319	$38.1K
Jun 13, 2025	Fletcher Aaron G.L. 10% owner	Sale	1,903	$5.9K
Jun 13, 2025	Fletcher Aaron G.L. 10% owner	Sale	4,354	$13.5K
Jun 13, 2025	Kreis Leslie W. 10% owner	Sale	1,903	$5.9K
Jun 13, 2025	Kreis Leslie W. 10% owner	Sale	7,206	$22.3K
Jun 13, 2025	Fletcher Aaron G.L. 10% owner	Sale	12,319	$38.1K
Jun 13, 2025	Fletcher Aaron G.L. 10% owner	Sale	7,206	$22.3K
Jun 13, 2025	Fletcher Aaron G.L. 10% owner	Sale	14,218	$43.9K
Jun 13, 2025	Kreis Leslie W. 10% owner	Sale	4,354	$13.5K
Jun 13, 2025	Kreis Leslie W. 10% owner	Sale	14,218	$43.9K
Jun 12, 2025	Kreis Leslie W. 10% owner	Sale	10,925	$36.9K
Jun 12, 2025	Kreis Leslie W. 10% owner	Sale	21,557	$72.9K
Jun 12, 2025	Kreis Leslie W. 10% owner	Sale	18,678	$63.1K
Jun 12, 2025	Fletcher Aaron G.L. 10% owner	Sale	10,925	$36.9K
Jun 12, 2025	Fletcher Aaron G.L. 10% owner	Sale	21,557	$72.9K
Jun 12, 2025	Kreis Leslie W. 10% owner	Sale	6,601	$22.3K
Jun 12, 2025	Fletcher Aaron G.L. 10% owner	Sale	2,886	$9.8K
Jun 12, 2025	Fletcher Aaron G.L. 10% owner	Sale	6,601	$22.3K
Jun 12, 2025	Kreis Leslie W. 10% owner	Sale	2,886	$9.8K
Jun 12, 2025	Fletcher Aaron G.L. 10% owner	Sale	18,678	$63.1K
Jun 11, 2025	Fletcher Aaron G.L. 10% owner	Sale	171	$581
Jun 11, 2025	Kreis Leslie W. 10% owner	Sale	171	$581
Jun 11, 2025	Kreis Leslie W. 10% owner	Sale	293	$996
Jun 11, 2025	Kreis Leslie W. 10% owner	Sale	45	$153
Jun 11, 2025	Kreis Leslie W. 10% owner	Sale	338	$1.1K
Jun 11, 2025	Kreis Leslie W. 10% owner	Sale	103	$350
Jun 11, 2025	Fletcher Aaron G.L. 10% owner	Sale	293	$996
Jun 11, 2025	Fletcher Aaron G.L. 10% owner	Sale	45	$153
Jun 11, 2025	Fletcher Aaron G.L. 10% owner	Sale	338	$1.1K
Jun 11, 2025	Fletcher Aaron G.L. 10% owner	Sale	103	$350
Jun 10, 2025	Fletcher Aaron G.L. 10% owner	Sale	2	$7
Jun 10, 2025	Fletcher Aaron G.L. 10% owner	Sale	5	$17
Jun 10, 2025	Fletcher Aaron G.L. 10% owner	Sale	1	$3
Jun 10, 2025	Fletcher Aaron G.L. 10% owner	Sale	5	$17
Jun 10, 2025	Fletcher Aaron G.L. 10% owner	Sale	3	$10
Jun 10, 2025	Kreis Leslie W. 10% owner	Sale	2	$7
Jun 10, 2025	Kreis Leslie W. 10% owner	Sale	5	$17
Jun 10, 2025	Kreis Leslie W. 10% owner	Sale	1	$3
Jun 10, 2025	Kreis Leslie W. 10% owner	Sale	5	$17
Jun 10, 2025	Kreis Leslie W. 10% owner	Sale	3	$10
May 29, 2025	Fletcher Aaron G.L. 10% owner	Sale	2,199	$6.7K
May 29, 2025	Kreis Leslie W. 10% owner	Sale	3,639	$11.0K
May 29, 2025	Kreis Leslie W. 10% owner	Sale	6,221	$18.8K
May 29, 2025	Kreis Leslie W. 10% owner	Sale	961	$2.9K
May 29, 2025	Kreis Leslie W. 10% owner	Sale	7,180	$21.8K
May 29, 2025	Kreis Leslie W. 10% owner	Sale	2,199	$6.7K
May 29, 2025	Fletcher Aaron G.L. 10% owner	Sale	3,639	$11.0K
May 29, 2025	Fletcher Aaron G.L. 10% owner	Sale	6,221	$18.8K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for Lantern Pharma Inc.

Free account. Everything above stays public.

Write why you follow Lantern Pharma Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading